Feedback AI Stock Analysis
Want to see GB:FDBK full AI Analyst Report?
Feedback (FDBK) AI Stock Analysis
Feedback
(LSE:FDBK)
The overall score is at the minimum of 37, reflecting a company in severe distress across all evaluated dimensions. The most significant factor is the dire financial performance, marked by collapsing revenue, margins, and accelerating cash burn that threatens the company's survival. This is compounded by a deeply bearish technical trend with the stock price below all key moving averages and extremely weak momentum. The negative P/E ratio confirms a lack of earnings power, providing no valuation support. The debt-free balance sheet is the only mitigating factor, but it is being rapidly eroded by ongoing losses.
Feedback (FDBK) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 1.56M
- Dividend Yield
- ―
- Average Volume (3M)
- 95.21K
- Price to Earnings (P/E)
- -0.4
- Beta (1Y)
- 0.65
- Revenue Growth
- -11.91%
- EPS Growth
- 69.57%
- Country
- UK
- Employees
- 26
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
Feedback Business Overview & Revenue Model
Company Description
Feedback plc is a medical technology company, headquartered in London, UK, and established in 1958, that supplies specialized software and systems to individuals and organizations working within the medical imaging sector. Their product portfolio inc...
Feedback Financial Statement Overview
Summary
Financial health is critically weak. Revenue is in steep decline, gross margins have collapsed from over 90% to 45.6%, and the net loss margin is -447%. The only positive is a debt-free balance sheet, but equity is eroding rapidly and cash burn is severe, with negative free cash flow threatening the company's viability.
Income Statement
18Very NegativeBalance Sheet
55NeutralCash Flow
10Very Negative| Breakdown | TTM | May 2025 | May 2024 | May 2023 | May 2022 | May 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 780.14K | 780.14K | 885.62K | 1.18M | 1.02M | 588.58K |
| Gross Profit | 355.77K | 355.77K | 778.65K | 1.10M | 131.39K | -63.68K |
| EBITDA | -3.18M | -3.13M | -3.06M | -2.73M | -2.61M | -1.96M |
| Net Income | -3.49M | -3.49M | -7.32M | -3.30M | -2.92M | -2.12M |
Balance Sheet | ||||||
| Total Assets | 3.42M | 3.42M | 6.75M | 8.34M | 11.72M | 14.30M |
| Cash, Cash Equivalents and Short-Term Investments | 2.73M | 2.73M | 5.95M | 3.88M | 7.32M | 10.31M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 663.97K | 663.97K | 589.02K | 694.18K | 855.45K | 594.13K |
| Stockholders Equity | 2.75M | 2.75M | 6.16M | 7.64M | 10.87M | 13.71M |
Cash Flow | ||||||
| Free Cash Flow | -2.79M | -2.79M | -2.83M | -2.14M | -2.99M | -2.41M |
| Operating Cash Flow | -2.79M | -2.79M | -2.82M | -2.22M | -1.74M | -1.25M |
| Investing Cash Flow | -429.54K | -429.54K | -716.00K | -1.22M | -1.24M | -1.15M |
| Financing Cash Flow | 0 | 0 | 5.61M | 0 | -830 | 10.49M |
Feedback Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:FDBK, the sentiment is Negative. The current price of 3.55 is below the 20-day moving average (MA) of 5.28, below the 50-day MA of 6.03, and below the 200-day MA of 8.49, indicating a bearish trend. The MACD of -0.75 indicates Positive momentum. The RSI at 14.06 is Positive, neither overbought nor oversold. The STOCH value of 1.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:FDBK.
Feedback Peers Comparison
Overall Rating
GB:KOO81Outperform
GB:IXI55Neutral
GB:GDR49Neutral
GB:COG41Neutral
GB:OBD40Underperform
GB:FDBK37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 81Outperform | GBP 67.37M | 11.22 | 17.74% | ― | -6.51% | 108.62% | |
| 55Neutral | GBP 27.92M | -6.50 | -16.18% | ― | 13.04% | 15.88% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | GBP 14.45M | -0.82 | -1044.57% | ― | 65.60% | 74.84% | |
| 41Neutral | GBP 15.65M | -9.63 | -54.17% | ― | 11.86% | 23.81% | |
| 40Underperform | GBP 15.46M | -0.29 | -451.74% | ― | 33.37% | 86.41% | |
| 37Underperform | GBP 1.56M | -0.45 | -96.66% | ― | -11.91% | 69.57% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:FDBK | Feedback plc | 3.55 | -5.05 | -58.72% | |
| GB:COG | Cambridge Cognition Holdings | 29.00 | -4.00 | -12.12% | |
| GB:GDR | Genedrive plc | 0.90 | -0.04 | -4.56% | |
| GB:IXI | IXICO plc | 12.75 | 1.75 | 15.91% | |
| GB:OBD | Oxford BioDynamics | 0.12 | -0.17 | -58.93% | |
| GB:KOO | Kooth Plc | 181.00 | 53.50 | 41.96% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 10, 2026
